Your browser doesn't support javascript.
loading
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
McMillan, Annabel; O'Neill, Aideen T; Townsend, William; Lambert, Jonathan; Virchis, Andres; Shah, Raakhee; Menezes, Leon; Humphries, Paul; Von Both, Kirsten; Grandage, Victoria; Carpenter, Ben; Hough, Rachael; Ardeshna, Kirit M; Daw, Stephen.
Afiliação
  • McMillan A; University College London Hospitals NHS Foundation Trust, London, UK.
  • O'Neill AT; University College London Hospitals NHS Foundation Trust, London, UK.
  • Townsend W; University College London Hospitals NHS Foundation Trust, London, UK.
  • Lambert J; University College London Hospitals NHS Foundation Trust, London, UK.
  • Virchis A; University College London Hospitals NHS Foundation Trust, London, UK.
  • Shah R; University College London Hospitals NHS Foundation Trust, London, UK.
  • Menezes L; University College London Hospitals NHS Foundation Trust, London, UK.
  • Humphries P; University College London Hospitals NHS Foundation Trust, London, UK.
  • Von Both K; University College London Hospitals NHS Foundation Trust, London, UK.
  • Grandage V; University College London Hospitals NHS Foundation Trust, London, UK.
  • Carpenter B; University College London Hospitals NHS Foundation Trust, London, UK.
  • Hough R; University College London Hospitals NHS Foundation Trust, London, UK.
  • Ardeshna KM; University College London Hospitals NHS Foundation Trust, London, UK.
  • Daw S; University College London Hospitals NHS Foundation Trust, London, UK.
Br J Haematol ; 192(3): e84-e87, 2021 02.
Article em En | MEDLINE | ID: mdl-33426648
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Cloridrato de Bendamustina / Brentuximab Vedotin / Recidiva Local de Neoplasia Tipo de estudo: Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Br J Haematol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Cloridrato de Bendamustina / Brentuximab Vedotin / Recidiva Local de Neoplasia Tipo de estudo: Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Br J Haematol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido